An agent biologically similar to the humanized monoclonal antibody natalizumab is as effective and safe as the original reference drug for relapsing-remitting multiple sclerosis (RRMS) — and has a ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Results from the EVOLVE-MS-1 study show Vumerity was ...

The goal of this double-blind, adaptive, dose-ranging, phase 2 study was to assess safety, tolerability and dose-response characteristics of siponimod and its effects on brain MRI lesion activity in ...

—To some extent, yes, say the results of a recent systematic review and meta-analysis. But were escalation therapies any more effective than platform therapies in boosting cognition? Share on Facebook ...

Lower nucleus accumbens volume independently predicts depressive symptoms and future anhedonia in patients with early relapsing-remitting MS.

Rituximab may be an attractive treatment option for patients with relapsing-remitting multiple sclerosis (MS), suggest phase II study findings showing its efficacy in controlling inflammatory activity ...

Please provide your email address to receive an email when new articles are posted on . Top-line results of a phase 2 clinical trial for an adipose-derived autologous mesenchymal stem cell therapy to ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Multiple ...

Good physical performance is associated with better cognition in people with relapsing-remitting MS, according to a recent study by the University of Eastern Finland. Good functional capacity was also ...

Dear Doctors: My older brother is 33 years old and was recently diagnosed with multiple sclerosis. I don’t want to bother him with a lot of questions, but I would like to learn more about it. Can you ...